217
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Hydrogen sulfide attenuates hyperhomocysteinemia-induced blood-brain barrier permeability by inhibiting MMP-9

&
Pages 1061-1071 | Received 17 Apr 2020, Accepted 13 Nov 2020, Published online: 01 Feb 2021
 

Abstract

Backgroud: Hyperhomocysteinemia (HHcy) is implicated in various neurovascular disorders including vascular dementia, subarachnoid hemorrhage and stroke. Elevated homocysteine (Hcy) levels are associated with increased oxidative stress and compromised blood–brain barrier (BBB) integrity. Hydrogen sulfide (H2S) has recently emerged as potent neuroprotective molecule in various neurological conditions including those associated with HHcy. The present study evaluates the protective effect of sodium hydrogen sulfide (NaHS; a source of H2S) on HHcy-induced BBB dysfunction and underpin molecular mechanisms.

Materials and methods: Supplementation of NaHS restored the increased BBB permeability in the cortex and hippocampus of HHcy animals assessed in terms of diffused sodium fluorescein and Evans blue tracer dyes in the brain. Activity of matrix metalloproteinases (MMPs) assessed by gelatinase activity and in situ gelatinase assay was restored to the normal in the cortex and hippocampus of HHcy animals supplemented with NaHS.

Results: Application of gelatin zymography revealed that specifically MMP-9 activity was increased in the cortex and hippocampus of HHcy animals, which was inhibited by NaHS supplementation. Real-time RT-PCR analysis showed that NaHS administration also decreased mRNA expression of MMP-9 in the hippocampus of HHcy animals. NaHS supplementation was further observed to reduce water retention in the brain regions of Hcy treated animals.

Conclusion: Taken together, these findings suggest that NaHS supplementation ameliorates HHcy-induced BBB permeability and brain edema by inhibiting the mRNA expression and activity of MMP-9. Therefore, H2S and H2S releasing drugs may be used as a novel therapeutic approach to treat HHcy-associated neurovascular disorders.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions

M.K. designed the study, performed the experiments, analyzed the data and prepared first draft of the manuscript. R.S. supervised the study and revised the manuscript. All authors have read and approved the final version of the manuscript.

Additional information

Funding

The financial assistance provided by the Department of Biotechnology (DBT), Govt. of India, (grant number BT/361/NE/TBP/2012) is acknowledged. The fellowship to MK from the University Grants Commission (UGC), New Delhi [F.17-7(J)/2004(SA-1)] is also acknowledged. The authors also acknowledge financial assistance provided under the promotion of University Research and Scientific Excellence (PURSE) by Department of Science and Technology (DST) New Delhi and under Special Assistance Program (SAP) of UGC (DRS Phase-II).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.